Researchers studied whether losartan, a common blood pressure medication, could help prevent nerve pain caused by paclitaxel chemotherapy in women with early-stage breast cancer. The trial included 89 women at one medical center who were scheduled for weekly paclitaxel treatment. Half received losartan daily along with their standard care, while the other half received standard care alone.
After 12 weeks, the group taking losartan had much lower rates of moderate-to-severe nerve pain (33% vs. 86% in the control group). They also reported better quality of life, less pain intensity, and took longer to develop neuropathy symptoms. Safety appeared similar between groups, though detailed safety information wasn't fully reported.
This was a small, single-center study where both patients and doctors knew who was receiving losartan, which could influence how symptoms were reported. The results are promising but preliminary. Larger studies at multiple centers are needed to confirm whether losartan truly helps prevent this chemotherapy side effect before doctors can recommend it routinely.
